Nubratori, Inc., Torrance

FDA 503B registration status

FDA 503B list ✓ (current 2026-07-14)

Nubratori, Inc., Torrance appears on FDA's registered outsourcing facilities list, parsed from Veritura's capture of that list (FDA list current as of 2026-07-14, captured 2026-07-17). Registration status can change between captures; the FDA page is the authoritative current source.

On our captures

On FDA's list since we began tracking captures on 2026-07-11 (tracking began 2026-07-10; we make no claim about FDA's list before our first capture). Last confirmed on our 2026-07-17 capture (FDA list current as of 2026-07-14).

Dates are Veritura's own capture dates of FDA's public list, shown next to FDA's list-current date wherever we have it. Public-record posture, not a determination.

FDA enforcement timeline

1 dated enforcement record matched this firm name in openFDA when this check last completed.

• 2025-04-15 · drug · Class II · Ongoing
  Labeling: Incorrect or Missing Lot and/or Expiration date: Individual vials of Dexonto 0.4%, are labeled correctly with the BUD of 12/25/2024, however, the outer box on some of the Dexonto 0.4% are la

Source: openFDA enforcement records (drug/device/food, updated weekly), checked 2026-07-18. Dated public records matching this firm name; similar firm names collide in public records, so confirm the firm identity against the source records before relying. Public-record posture, not a determination.

Live FDA enforcement screen

1 enforcement record match on this firm name in openFDA when this screen last ran. Review the underlying public records and confirm the firm identity before relying on this signal.

0 FDA compliance action records matched this name.

Source: openFDA enforcement records and FDA compliance dashboards, refreshed at most every 6 hours. A count here documents what public sources returned for this name (searched: Nubratori, Inc., Torrance); it is not a Veritura determination about the facility.

Reported products

13 distinct products as reported to FDA in 503B product reports (data vintage: reporting periods 2025-2, 2025-1).

• Baclofen · 50 mg/1 g · cream · reported period 2025-2
• Baclofen · 20 mg/1 g · cream · reported period 2025-2
• Dexamethasone Sodium Phosphate · 4 mg/1 mL · solution · reported period 2025-2
• Dexamethasone Sodium Phosphate; Lidocaine Hydrochloride · 3.33 mg/1 mL; 6.67 mg/1 mL · injection, solution · reported period 2025-2
• Diclofenac Sodium · 100 mg · suppository · reported period 2025-2
• Gabapentin · 100 mg/1 g · cream · reported period 2025-2
• Ketamine Hydrochloride · 50 mg/1 g · cream · reported period 2025-2
• Ketoprofen · 100 mg/1 g · cream · reported period 2025-2
• Lidocaine · 75 mg/1 g · cream · reported period 2025-2
• Naltrexone Hydrochloride · 1.5 mg · capsule · reported period 2025-2
• Naltrexone Hydrochloride · 4.5 mg · capsule · reported period 2025-2
• Epinephrine · .2 mg/.2 mL · injection · reported period 2025-1
• Lidocaine Hydrochloride; Tetracaine Hydrochloride · 4 mg/1 mL; 2 mg/1 mL · injection · reported period 2025-1

Source: FDA outsourcing facility product reports (FD&C 503B(b)(2)). Retrospective by design: a row means the facility reported compounding this product to FDA in the named period, never that it currently compounds, can supply, or is endorsed for it. Public-record posture, not a determination.

Watch this facility

Get an email if this facility's FDA list status or enforcement record changes between our captures. Public-record change notices only; every email carries a one-click unsubscribe link.

Is this your facility?

Claim this profile to keep it accurate and attach your own documentation through Veritura. Every claim is verified by hand before anything changes.